|
09 Jan 2020 |
CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis
|
|
09 Jan 2020 |
Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
|
|
09 Jan 2020 |
Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401
|
|
08 Jan 2020 |
Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation
|
|
07 Jan 2020 |
Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise
|
|
06 Jan 2020 |
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
|
|
30 Dec 2019 |
Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
|
30 Dec 2019 |
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
21 Dec 2019 |
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
|
|
21 Dec 2019 |
Aravive Initiates a Phase 2a Clinical Trial of AVB-500 in Patients with Kidney Fibrosis
|
|
21 Dec 2019 |
Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
|
|
20 Dec 2019 |
Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich’s Ataxia
|
|
20 Dec 2019 |
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
|
|
20 Dec 2019 |
Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma
|
|
20 Dec 2019 |
Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
|
|
18 Dec 2019 |
DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease
|
|
16 Dec 2019 |
Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency
|
|
13 Dec 2019 |
BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
|
|
11 Dec 2019 |
Navigen Announces FDA Clearance of its IND Application to Initiate First-in-Human Studies for CPT31, a Novel, D-peptide HIV Entry Inhibitor
|
|
10 Dec 2019 |
BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors
|
|
10 Dec 2019 |
ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
|
|
08 Dec 2019 |
Molecular Partners Presents Updated Results of MP0250 in Patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology
|
|
08 Dec 2019 |
Grifols presents its latest Alzheimer's clinical trial data
|
|
06 Dec 2019 |
Fibriant Expands License Adding Recombinant Human (pro)thrombin to Existing Recombinant Fibrinogen Capability
|
|
05 Dec 2019 |
Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities
|
